Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI
Prostate Cancer: New ESTRO Recommendations for Precision Radiotherapy
Monica Bertagnolli: Don't Abolish the NIH, Fix It
Can SABR Replace Surgery in Selected Low-Risk Breast Cancer?
Felicia Marie Knaul: WHO to Present First Global Estimates of 5-Year Breast Cancer Survival
BOT/BAL Shows 33% 3-Year OS in Refractory MSS mCRC Without Active Liver Metastases
Daraxonrasib for Pancreatic Cancer: What’s Next?
ESTRO Sets Practical Guidance for Focal Boosting in Prostate Cancer Radiotherapy 2026
